CN109563133A - 多酰胺化合物及其用途 - Google Patents

多酰胺化合物及其用途 Download PDF

Info

Publication number
CN109563133A
CN109563133A CN201780046820.6A CN201780046820A CN109563133A CN 109563133 A CN109563133 A CN 109563133A CN 201780046820 A CN201780046820 A CN 201780046820A CN 109563133 A CN109563133 A CN 109563133A
Authority
CN
China
Prior art keywords
amino
compound
group
phenylpropionyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780046820.6A
Other languages
English (en)
Other versions
CN109563133B (zh
Inventor
蔡家强
田强
赵明亮
曾宏
宋宏梅
郁楠
邓华
钟维
杨龙
吴雷
黄海涛
吴勇勇
苏东海
周信
谭玉婷
王利春
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN109563133A publication Critical patent/CN109563133A/zh
Application granted granted Critical
Publication of CN109563133B publication Critical patent/CN109563133B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及多酰胺化合物及其用途，具体地，本发明涉及一类多酰胺化合物(其优选含有由相同或不同的L‑氨基酸或D‑氨基酸缩合形成的一个或多个酰胺键)、或其立体异构体、多晶型物、溶剂合物、或其代谢物、前药或药学上可接受的盐或酯、或其药物组合物，以及该类多酰胺化合物的制备方法及其在预防或治疗与κ阿片样物质受体相关的疾病中的用途。本发明的多酰胺化合物具有优异的κ阿片样物质受体激动效能、亲水能力和由此更小的穿透血脑屏障以及更低的进入脑部的能力。本发明的化合物对于κ阿片样物质受体更高的选择性、更低的成瘾性、改善的药物代谢动力学性质、改善的安全性(较低的毒性和/或较少的副作用、良好的患者顺应性，和/或较不易产生耐受性等更优异的成药性质。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201780046820.6A 2016-09-27 2017-09-22 多酰胺化合物及其用途 Active CN109563133B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610852604 2016-09-27
CN2016108526048 2016-09-27
PCT/CN2017/103027 WO2018059331A1 (zh) 2016-09-27 2017-09-22 多酰胺化合物及其用途

Publications (2)

Publication Number Publication Date
CN109563133A true CN109563133A (zh) 2019-04-02
CN109563133B CN109563133B (zh) 2020-09-11

Family

ID=61762536

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780046820.6A Active CN109563133B (zh) 2016-09-27 2017-09-22 多酰胺化合物及其用途

Country Status (6)

Country Link
US (1) US11084847B2 (zh)
EP (1) EP3521301B1 (zh)
JP (1) JP6794602B2 (zh)
CN (1) CN109563133B (zh)
PH (1) PH12019500199A1 (zh)
WO (1) WO2018059331A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493490A (zh) * 2020-04-03 2021-10-12 成都诺和晟泰生物科技有限公司 一种合成肽酰胺类化合物及其在医药领域的用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111868070A (zh) * 2018-05-15 2020-10-30 四川科伦博泰生物医药股份有限公司 一种多肽的纯化方法
US20210355166A1 (en) * 2018-05-31 2021-11-18 The University Of Sydney Analgesics and methods of use thereof
CN112739709A (zh) * 2018-11-15 2021-04-30 四川科伦博泰生物医药股份有限公司 含有多肽类化合物的药物组合物及其制备方法和用途
WO2021026492A1 (en) * 2019-08-07 2021-02-11 Humanwell Pharmaceutical US Kappa opioid receptor peptide amide agonists
WO2021047470A1 (zh) * 2019-09-10 2021-03-18 四川海思科制药有限公司 一种肽酰胺类化合物及其中间体的制备方法
CN110790817A (zh) 2019-11-12 2020-02-14 成都诺和晟泰生物科技有限公司 一种多肽类化合物、制剂、药物组合物及制备方法、应用
JP2023536221A (ja) * 2020-06-25 2023-08-24 ヒューマンウェル ファーマシューティカル ユーエス 医学的障害の治療のためのペプチド
TW202337460A (zh) * 2022-03-23 2023-10-01 大陸商江蘇恩華藥業股份有限公司 多醯胺類化合物、其製備方法及其醫藥用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032510A1 (en) * 1997-12-23 1999-07-01 Ferring B.V. Kappa receptor opioid peptides
WO2003092688A2 (en) * 2002-04-29 2003-11-13 Janssen Pharmaceutica N.V. Heterocyclic derivatives as opioid modulators
CN101535336A (zh) * 2006-11-10 2009-09-16 卡拉治疗学股份有限公司 合成酞酰胺及其二聚体
CN101627049A (zh) * 2006-11-10 2010-01-13 卡拉治疗学股份有限公司 合成酞酰胺
WO2013184794A2 (en) * 2012-06-05 2013-12-12 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
TW201601743A (zh) * 2013-10-28 2016-01-16 卡拉治療股份有限公司 外周ｋａｐｐａ鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途
CN107098871A (zh) * 2016-02-23 2017-08-29 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142379A1 (en) 2003-01-16 2004-07-22 Carlsberg Research Laboratory Affinity fishing for ligands and proteins receptors
US20170007574A1 (en) 2015-07-02 2017-01-12 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for uremic pruritus in dialysis patients
US20180078605A1 (en) 2006-11-10 2018-03-22 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for uremic pruritus in dialysis patients
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
MX2016016479A (es) 2014-06-26 2017-04-10 Maruishi Pharma Metodo para producir un pentapeptido sintetico.
US20180028594A1 (en) 2014-11-05 2018-02-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for hard tissue pain
JP6651546B2 (ja) 2015-05-11 2020-02-19 カディラ・ヘルスケア・リミテッド カッパ（κ）オピオイド受容体（ＫＯＲ）アゴニストとしての新規の短鎖ペプチド
CN108290926B (zh) 2016-06-07 2022-02-08 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032510A1 (en) * 1997-12-23 1999-07-01 Ferring B.V. Kappa receptor opioid peptides
WO2003092688A2 (en) * 2002-04-29 2003-11-13 Janssen Pharmaceutica N.V. Heterocyclic derivatives as opioid modulators
CN101535336A (zh) * 2006-11-10 2009-09-16 卡拉治疗学股份有限公司 合成酞酰胺及其二聚体
CN101627049A (zh) * 2006-11-10 2010-01-13 卡拉治疗学股份有限公司 合成酞酰胺
WO2013184794A2 (en) * 2012-06-05 2013-12-12 Cara Therapeutics, Inc. Peripheral kappa receptor agonists for reducing pain and inflammation
TW201601743A (zh) * 2013-10-28 2016-01-16 卡拉治療股份有限公司 外周ｋａｐｐａ鴉片受體促進劑用於製備預防、抑制或治療噁心及嘔吐之藥物的用途
CN107098871A (zh) * 2016-02-23 2017-08-29 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493490A (zh) * 2020-04-03 2021-10-12 成都诺和晟泰生物科技有限公司 一种合成肽酰胺类化合物及其在医药领域的用途
CN113493490B (zh) * 2020-04-03 2024-03-12 成都诺和晟泰生物科技有限公司 一种合成肽酰胺类化合物及其在医药领域的用途

Also Published As

Publication number Publication date
JP6794602B2 (ja) 2020-12-02
US11084847B2 (en) 2021-08-10
EP3521301A4 (en) 2020-05-27
US20200109166A1 (en) 2020-04-09
EP3521301A1 (en) 2019-08-07
CN109563133B (zh) 2020-09-11
JP2019526538A (ja) 2019-09-19
EP3521301B1 (en) 2024-03-06
WO2018059331A1 (zh) 2018-04-05
PH12019500199A1 (en) 2019-10-21

Similar Documents

Publication Publication Date Title
CN109563133A (zh) 多酰胺化合物及其用途
ES2881395T3 (es) Composiciones y métodos para inhibir la actividad de la arginasa
EP2252150B1 (en) Selective opioid compounds
AU2005227258A1 (en) HIV integrase inhibitors
PT869968E (pt) Secretagogos de hormona do crescimento.
KR20230160804A (ko) 프로드러그 화합물 및 이의 제조 방법과 용도
IL298887A (en) Small molecule modulators of IL-17
ES2894324T3 (es) Derivados del dextrorfano con actividad nerviosa central suprimida
CA3180729A1 (en) Peptides for treatment of medical disorders
AU2021326929A1 (en) Aromatic ring-lactam compound, preparation method therefor and use thereof
CN111315758A (zh) 短肽季铵盐化合物及其用途
WO2024015106A1 (en) Peptides for treatment of medical disorders
WO2020050378A1 (ja) 第３級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
WO2024019995A1 (en) Quinoxalinedione and pyrido [2, 3-b]pyrazine-2, 3-dione b cell lymphoma 6 (bcl6) degraders and uses thereof
WO2024118966A1 (en) Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof
CN117567460A (zh) 一种前药化合物及其制备方法和用途
CA3174252A1 (en) Compounds active towards nuclear receptors
CA3194724A1 (en) Potent and selective inhibitors of her2
WO2024086094A1 (en) Alkylamine-containing small molecule degraders of bcl6
CN116801878A (zh) Her2的有效和选择性抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004336

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant